非霍奇金淋巴瘤患者异基因造血细胞移植后 EB 病毒和巨细胞病毒再激活：发生率及对结局的影响：NHL 患者 allo-HCT 后 EBV 和 CMV 再激活

Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivations are common complications after allogeneic hematopoietic cell transplantation (allo-HCT), but data focusing on non-Hodgkin lymphoma (NHL) are limited.

We retrospectively analyzed the prevalence of EBV and CMV reactivation post-allo-HCT and the impacts on transplant outcomes in 160 NHL patients. The 1-year incidences of EBV and CMV reactivation were 22. 58% and 25. 55%, respectively. Independent impactors for EBV reactivation were more than 6 lines of chemotherapy (P = 0. 030), use of rituximab (P = 0. 004), and neutrophil recovery within 30 days post-HCT (P = 0. 022). For T-cell lymphoblastic lymphoma patients, the International Prognostic Index (IPI) (P = 0.

015) and chronic GVHD (P = 0. 001) increased the risk of CMV reactivation. CMV reactivation was independently related to a lower risk of relapse (P = 0. 027) but higher transplant-related mortality (TRM) (P = 0. 038). Although viral reactivation had no significant impact on overall survival (OS) in the whole cohort, it led to an inferior 2-year OS (67. 6% versus 92. 5%, P = 0. 005) and TRM (20. 1% versus 4. 7%, P = 0. 020) in recipients surviving for more than 180 days.

We concluded that EBV and CMV reactivation post-allotransplant still deserved concern particularly in NHL patients with high-risk factors, since it is generally related to a deteriorated prognosis. Large-scale studies are warranted to validate our findings.